Search Result

Results for "

hepatitis C virus NS5A

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HCV (29) Endogenous Metabolite (1) Fluorescent Dye (1) HCV Protease (6) Isotope-Labeled Compounds (6) Liposome (1) Reference Standards (3) SARS-CoV (8)
By Research Areas:	Cancer (5) Infection (35) Inflammation/Immunology (6)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Peptides

Isotope-Labeled Compounds

Targets Recommended: Hepatitis E Virus (HEV) HCV HBV

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-15602

Ledipasvir Maximum Cited Publications 31 Publications Verification GS-5885	HCV SARS-CoV	Infection
Ledipasvir (GS-5885) is an inhibitor of the **hepatitis C virus NS5A, with EC₅₀s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀** of 1.62 μM .

HY-12530

Velpatasvir 5+ Cited Publications GS-5816	HCV SARS-CoV	Infection Inflammation/Immunology Cancer
Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 2.16 μM .

HY-15789

Elbasvir 5+ Cited Publications MK-8742	HCV	Infection
Elbasvir (MK-8742) is a hepatitis C virus nonstructural protein 5A (HCV NS5A) inhibitor with EC₅₀s of 4, 3 and 3 nM against genotype 1a, 1b, and 2a, respectively.

HY-101662

Pibrentasvir ABT-530	HCV	Infection
Pibrentasvir is a novel and pan-genotypic **hepatitis C virus (HCV) NS5A inhibitor with EC₅₀*s ranging from 1.4 to 5.0 pM against HCV replicons containing NS5A* from genotypes 1 to 6.

HY-13997

Ombitasvir 5+ Cited Publications ABT-267	HCV	Infection
Ombitasvir is a potent inhibitor of the **hepatitis C virus protein NS5A, with EC₅₀**s of 0.82 to 19.3 pM against HCV genotypes 1 to 5, and 366 pM against genotype 6a.

HY-15602B

Ledipasvir D-tartrate Maximum Cited Publications 31 Publications Verification GS-5885 D-tartrate	HCV	Infection
Ledipasvir D-tartrate is an inhibitor of the **hepatitis C virus NS5A, with EC₅₀** values of 34 pM against GT1a and 4 pM against GT1b replicon.

HY-P5366

PEP1	Liposome	Others
PEP1 is an amphipathic α-helical peptide containing 31 residues. The interaction of PEP1 with POPC-supported lipid bilayers (SLBs) is concentration-dependent: at low concentrations, it inserts into SLBs to generate compressive stress; at medium concentrations, it saturates the membrane surface to maintain constant stress; and at high concentrations, it solubilizes SLBs. PEP1 can be used for research on the mechanism of membrane-peptide interactions .

HY-15602A

Ledipasvir (acetone) Maximum Cited Publications 31 Publications Verification GS-5885 (acetone)	HCV	Infection
Ledipasvir acetone (GS-5885 acetone) is the active ingredient of Ledipasvir. Ledipasvir is an inhibitor of the **hepatitis C virus NS5A, with EC₅₀** values of 34 pM against GT1a and 4 pM against GT1b replicon.

HY-147358

Yimitasvir diphosphate Emitasvir diphosphate; DAG-181 diphosphate	HCV	Infection
Yimitasvir diphosphate (Emitasvir diphosphate; DAG-181 diphosphate) is an orally active inhibitor of hepatitis C virus (HCV) nonstructural protein 5A (NS5A). Yimitasvir diphosphate is applicable to research related to HCV infection .

HY-124191

Ravidasvir hydrochloride PPI-668 hydrochloride	HCV	Infection
Ravidasvir hydrochloride (PPI-668 hydrochloride) is a pan-genotypic inhibitor for **hepatitis C virus** (HCV) NS5A protein. Ravidasvir hydrochloride inhibits the replication of HCV, with EC₅₀ of 0.12, 0.01 and 1.14 nM, for HCV gt-1a, gt-1b, and gt-3a replicons, respectively. Ravidasvir hydrochloride exhibits good pharmacokinetic characters in rats .

HY-117411A

Coblopasvir dihydrochloride KW-136 dihydrochloride	HCV HCV Protease	Infection
Coblopasvir (KW-136) dihydrochloride is a pangenotypic non-structural protein 5A *(NS5A)* inhibitor. Coblopasvir dihydrochloride can be used for research of chronic hepatitis C virus infection .

HY-147358A

Yimitasvir Emitasvir; DAG-181	HCV	Infection
Yimitasvir (Emitasvir; DAG-181) is an orally active inhibitor of hepatitis C virus (HCV) nonstructural protein 5A (NS5A). Yimitasvir is applicable to research related to HCV infection .

HY-15602C

Ledipasvir hydrochloride GS-5885 hydrochloride	HCV SARS-CoV	Infection
Ledipasvir (GS-5885) hydrochloride is an inhibitor of the **hepatitis C virus NS5A, with EC₅₀s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir hydrochloride is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀** of 1.62 μM .

HY-12530R

Velpatasvir (Standard) GS-5816 (Standard)	Reference Standards HCV SARS-CoV	Infection Inflammation/Immunology Cancer
Velpatasvir (Standard) is the analytical standard of Velpatasvir. This product is intended for research and analytical applications. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 2.16 μM .

HY-117411

Coblopasvir KW-136	HCV HCV Protease	Infection Inflammation/Immunology
Coblopasvir (KW-136) is a pangenotypic non-structural protein 5A *(NS5A)* inhibitor. Coblopasvir can be used for research of chronic hepatitis C virus infection .

HY-124182

Odalasvir ACH-3102; JNJ64289901	HCV	Infection
Odalasvir (ACH-3102) is a potent and selective inhibitor of HCV NS5A, and can be used in research on hepatitis C virus infection .

HY-15602D

Ledipasvir (diacetone) GS-5885 (diacetone)	HCV	Infection
Ledipasvir diacetone (GS-5885 diacetone) is the active ingredient of Ledipasvir. Ledipasvir is an inhibitor of the **hepatitis C virus NS5A, with EC₅₀** values of 34 pM against GT1a and 4 pM against GT1b replicon.

HY-15602AS

Ledipasvir-d6 hydrochloride GS-5885-d6 hydrochloride	HCV Isotope-Labeled Compounds	Infection
Ledipasvir-d₆ hydrochloride is deuterated labeled Ledipasvir acetone (HY-15602A). Ledipasvir acetone (GS-5885 acetone) is the active ingredient of Ledipasvir. Ledipasvir is an inhibitor of the **hepatitis C virus NS5A, with EC₅₀** values of 34 pM against GT1a and 4 pM against GT1b replicon.

HY-147358C

(1R,4S)-Yimitasvir diphosphate (1R,4S)-Emitasvir diphosphate; (1R,4S)-DAG-181 diphosphate	HCV	Infection
Yimitasvir (Emitasvir) diphosphate is an orally active hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor and can be used for research of chronic hepatitis C virus infection .

HY-15789R

Elbasvir (Standard) MK-8742 (Standard)	Reference Standards HCV	Infection
Elbasvir (Standard) is the analytical standard of Elbasvir. This product is intended for research and analytical applications. Elbasvir (MK-8742) is a hepatitis C virus nonstructural protein 5A (HCV NS5A) inhibitor with EC₅₀s of 4, 3 and 3 nM against genotype 1a, 1b, and 2a, respectively.

HY-15602S

Ledipasvir-d6 GS-5885-d₆	HCV SARS-CoV	Infection
Ledipasvir-d₆ is the deuterium labeled Ledipasvir. Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC₅₀s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 1.62 μM .

HY-12530S1

Velpatasvir-d3 GS-5816-d3₃	Isotope-Labeled Compounds SARS-CoV HCV	Infection Inflammation/Immunology Cancer
Velpatasvir-d₃ (GS-5816-d₃) is deuterium labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 2.16 μM .

HY-117967

MK-6169	HCV Protease	Infection
MK-6169 is a potent, pan-genotypic hepatitis C virus *NS5A* inhibitor .

HY-P4038

Hepatitis C Virus S5A/5B	HCV Protease	Infection
Hepatitis C Virus S5A/5B is a synthetic peptide substrate. Hepatitis C Virus S5A/5B mimics the NS5A/5B junction of the nonstructural protein (NS), served as the substrate for the study of HCV NS3 protease activity .

HY-146126

NS5A-IN-4	HCV Protease	Infection
NS5A-IN-4 (Compound 1.12) is an orally active pan-genotypic **hepatitis C virus (HCV) NS5A inhibitor with IC₅₀ values of 1.2, 2296, 4.6, 362, 10.3 and 693 pM against gT1b, gT1a, gT2a, gT3a, gT4a and gT5a** . NS5A-IN-4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-13997R

Ombitasvir (Standard) ABT-267 (Standard)	HCV Reference Standards	Infection
Ombitasvir (Standard) is the analytical standard of Ombitasvir. This product is intended for research and analytical applications. Ombitasvir is a potent inhibitor of the hepatitis C virus protein NS5A, with EC50s of 0.82 to 19.3 pM against HCV genotypes 1 to 5, and 366 pM against genotype 6a.

HY-15602S1

Ledipasvir-d16 GS-5885-d₁₆	Isotope-Labeled Compounds HCV SARS-CoV	Infection
Ledipasvir-d₁₆ (GS-5885-d₁₆) is deuterium labeled Ledipasvir. Ledipasvir (GS-5885) is an inhibitor of the **hepatitis C virus NS5A, with EC₅₀s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀** of 1.62 μM .

HY-W749691

(S)-Velpatasvir-13c,d3 (S)-GS-5816-¹³C,d₃	Isotope-Labeled Compounds SARS-CoV HCV	Infection Inflammation/Immunology Cancer
(S)-Velpatasvir- ¹³C,d₃ ((S)-GS-5816- ¹³C,d₃) is ¹³C labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 2.16 μM ^.

HY-12530S3

Velpatasvir-13C,d3 GS-5816-¹³C,d₃	Isotope-Labeled Compounds	Infection Inflammation/Immunology Cancer
Velpatasvir- ¹³C,d₃ (GS-5816- ¹³C,d₃) is ¹³C and deuterium labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 2.16 μM .

HY-17619

Ravidasvir PPI-668	HCV	Infection
Ravidasvir (PPI-668) is an orally active pan-genotypic *NS5A* inhibitor and antiviral agent. Ravidasvir exhibits antiviral activity against HCV genotypes 1 to 6, with EC₅₀ values ranging from 0.04 to 1.14 nM. Ravidasvir shows no or extremely low activity against feline infectious peritonitis virus type II. Ravidasvir can be used in research related to hepatitis C virus infection .

HY-101662S

Pibrentasvir-d6 ABT-530-d₆	Isotope-Labeled Compounds HCV	Infection
Pibrentasvir-d₆ (ABT-530-d₆) is the deuterium labeled Pibrentasvir (HY-101662). Pibrentasvir is a novel and pan-genotypic **hepatitis C virus (HCV) NS5A inhibitor with EC₅₀*s ranging from 1.4 to 5.0 pM against HCV replicons containing NS5A* from genotypes 1 to 6.

HY-D2946

CLIP-TMR BC-TMR	Fluorescent Dye	Infection
CLIP-TMR (BC-TMR) is a TMR-labeled CLIP tag fluorescent probe. CLIP-TMR combines the high specificity recognition ability of the CLIP-tag and the excellent optical performance of the TMR fluorophore, and can be used for the specific labeling and visualization of the HCV NS5A protein .

HY-13321

Anguizole 2 Publications Verification	HCV	Infection
Anguizole is an HCV NS4B inhibitor. Anguizole interacts with NS4B-AH2, inhibits AH2 lipid vesicle aggregation, disrupts NS4B dimerization/multimerization and impairs NS4B-NS5A interaction. Anguizole exhibits little host cell toxicity. Anguizole can be used for the research of HCV infection .

HY-114216

DBPR110	Endogenous Metabolite	Infection
DBPR110 is a nonstructural protein 5A (NS5A) inhibitor with inhibitory activity against hepatitis C virus (HCV). DBPR110 exhibited a 50% effective concentration (EC50) of 3.9 ± 0.9 pM and a selectivity index value of over 12,800,000 by reducing HCV1b replicon reporter expression. DBPR110 also effectively reduced the activity of HCV2a replicon with an EC50 of 228.8 pM and a selectivity index value of over 173,130. DBPR110 showed synergy with interferon alpha (IFN-α), NS3 protease inhibitors, and NS5B polymerase inhibitors. The results of DBPR110 suggest that it may be an effective small molecule inhibitor against HCV NS5A .

HY-182691

Amphihevir	HCV	Infection
Amphihevir is an orally active HCV NS4B inhibitor. Amphihevir exhibits activity against HCV genotype 1a and 1b replicons and reduces HCV RNA levels. Amphihevir can be used in the research of chronic hepatitis C .

HY-108029

Deldeprevir sodium ACH-2684 sodium; Neceprevir sodium	HCV HCV Protease	Infection
Deldeprevir (ACH-2684; Neceprevir) sodium is a HCV NS3/4A protease inhibitor and resistance inhibitor. Deldeprevir sodium exhibits activity against wild-type genotype 1a and 1b HCV, including mutant strains resistant to other NS3 protease inhibitors. Deldeprevir sodium blocks the emergence of HCV mutant strains resistant to ACH-3422 in vitro, with enhanced efficacy when used in triple combination with ACH-3422 and ACH-3102 (HY-124182). Deldeprevir sodium shows additive antiviral potency when combined with ACH-3422, and exerts antiviral activity against HCV replicons carrying ACH-3102. Deldeprevir sodium is applicable to research related to hepatitis C .

Cat. No.	상품명

HY-L073

Anti-Hepatitis C Virus Compound Library	392 compounds
Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle. MCE offers a unique collection of 392 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Anti-Hepatitis C Virus Compound Library

392 compounds

Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle.

MCE offers a unique collection of 392 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

CLIP-TMR BC-TMR	Fluorescent Dyes
CLIP-TMR (BC-TMR) is a TMR-labeled CLIP tag fluorescent probe. CLIP-TMR combines the high specificity recognition ability of the CLIP-tag and the excellent optical performance of the TMR fluorophore, and can be used for the specific labeling and visualization of the HCV NS5A protein .

Cat. No.	상품명	Target	Research Area